156 related articles for article (PubMed ID: 11104568)
1. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease.
Doweck I; Barak M; Uri N; Greenberg E
Br J Cancer; 2000 Dec; 83(12):1696-701. PubMed ID: 11104568
[TBL] [Abstract][Full Text] [Related]
2. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
4. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
[TBL] [Abstract][Full Text] [Related]
5. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
[TBL] [Abstract][Full Text] [Related]
6. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
[TBL] [Abstract][Full Text] [Related]
7. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer.
Maass JD; Hoffmann-Fazel A; Goeroegh T; Hoffmann M; Meyer JE; Gottschlich S; Rudert H; Maune S
Anticancer Res; 2000; 20(3B):2241-3. PubMed ID: 10928185
[TBL] [Abstract][Full Text] [Related]
8. Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients.
Zhong LP; Zhang CP; Zheng JW; Li J; Chen WT; Zhang ZY
Arch Oral Biol; 2007 Nov; 52(11):1079-87. PubMed ID: 17612501
[TBL] [Abstract][Full Text] [Related]
9. [Contribution of serum Cyfra 21-1 in nasopharyngeal carcinoma in Tunisia].
Jmal A; Boussen H; Abdennebi M; Gara S; Harzallah L; Gritli S; Ladgham A; Guemira F; Ghanem A
Bull Cancer; 2004 Apr; 91(4):369-72. PubMed ID: 15242321
[TBL] [Abstract][Full Text] [Related]
10. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
12. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
Muley T; Fetz TH; Dienemann H; Hoffmann H; Herth FJ; Meister M; Ebert W
Lung Cancer; 2008 Jun; 60(3):408-15. PubMed ID: 18083270
[TBL] [Abstract][Full Text] [Related]
13. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
[TBL] [Abstract][Full Text] [Related]
14. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection.
Yeh JJ; Liu FY; Hsu WH; Wang JJ; Ho ST; Kao A
Lung; 2002; 180(5):273-9. PubMed ID: 12489021
[TBL] [Abstract][Full Text] [Related]
15. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
16. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Deng YF; Chen P; Lin YZ; Le JZ; Wu XL; Yu MQ; Zhuang PY; Gao MH
J Laryngol Otol; 2003 Mar; 117(3):190-4. PubMed ID: 12648374
[TBL] [Abstract][Full Text] [Related]
17. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma.
Nagler RM; Barak M; Peled M; Ben-Aryeh H; Filatov M; Laufer D
Cancer; 1999 Mar; 85(5):1018-25. PubMed ID: 10091783
[TBL] [Abstract][Full Text] [Related]
18. CYFRA 21-1 serum analysis in patients with esophageal cancer.
Brockmann JG; St Nottberg H; Glodny B; Heinecke A; Senninger NJ
Clin Cancer Res; 2000 Nov; 6(11):4249-52. PubMed ID: 11106239
[TBL] [Abstract][Full Text] [Related]
19. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
Lin WY; Yen TC; Cheng KY; Wang SJ
Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
[TBL] [Abstract][Full Text] [Related]
20. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
